We previously reported the clinical characteristics including the efficacy of first-generation somatostatin ligand (fg-SRL) in acromegaly patients with an increased growth hormone (GH) response to the oral glucose tolerance test (OGTT) or thyrotropin-releasing hormone (TRH) loading [1, 2]. The gene discussed is TRH; the disease is acromegaly.